PHARMACY

Amneal gets FDA approval for two generics

BY Sandra Levy

Amneal Pharmaceuticals has received the Food and Drug Administration’s blessing for chlorpromazine hydrochloride tablets in 10 mg, 25 mg, 50 mg, 100 mg and 200 mg dosage strengths.

Chlorpromazine hydrochloride tablets had a market value of approximately $207 million for the 12 months ended July 2018, according to IQVIA.

“Our large and diversified generic pipeline continues to deliver an industry leading number of approvals and launches in 2018,” Amneal president and CEO Rob Stewart, said. “The immediate launch of chlorpromazine hydrochloride tablets, a potentially high-value opportunity, further enhances our generic portfolio and our commitment to provide patients with a more affordable treatment option.”

In a separate development, Amneal also received the FDA’s nod for a generic version of methergine tablets, 0.2 mg (methylergonovine maleate tablet, 0.2 mg ).

Methylergonovine maleate tablets had a market value of approximately $73 million for the 12 months ending July 2018, according to IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Pharmacy groups applaud CMS’ rejection of below-cost Medicaid dispensing fees

BY Sandra Levy

The National Association of Chain Drug Stores, or NACDS, the Washington State Pharmacy Association, or WSPA, and the National Community Pharmacists Association, or NCPA, praised the Centers for Medicare & Medicaid Services, or CMS, for its rejection of Washington State’s below-cost and lowest-in-the-nation Medicaid pharmacy dispensing fees.

In 2016, CMS put a new rule in place, which changed states’ calculation of reimbursement to pharmacies for Medicaid prescriptions. A key part of the rule indicates that states must at least reimburse pharmacies for their actual costs in dispensing drugs to Medicaid beneficiaries. The associations have advocated in all branches and levels of government that Washington State’s below-cost reimbursement violates the new rule, jeopardizes reliable patient access to medications responsible for ensuring patient health, and leads to more costly forms of care that result from untreated conditions.

“This action by CMS should spur Washington State to increase its dispensing fees and demonstrate to other Medicaid programs that dispensing fees must cover pharmacies’ costs. This increase in dispensing fees must be supported by pharmacy cost data, and under federal rules should be applied retrospectively effective April 1, 2017. The State has indicated it plans to ask CMS to reconsider its decision,” the pharmacy groups said.

NACDS, WSPA, and NCPA issued a joint statement in support of CMS’ decision: “CMS has taken action that is consistent with the Covered Outpatient Drugs final rule and that is consistent with the health and wellness of our most vulnerable patients. We strongly support this pivotal development, which will prove highly significant for pharmacy patient care in Washington State and nationwide. We will continue to advocate in support of this pro-patient and pro-pharmacy position.”

In June of this year, NACDS, NCPA, and WSPA sent a letter to CMS asking the agency to “delay no longer in requiring Washington to comply with federal Medicaid reimbursement law like other states.”

In March 2017, NACDS, WSPA, and NCPA sued the State of Washington to stop a “substantively and procedurally flawed” rule that would pay community pharmacies below the actual cost to dispense Medicaid prescriptions. An important brief filed this summer in the Washington State Court of Appeals described the associations’ position in great detail. NACDS, WSPA and NCPA are continuing their litigation challenging the state’s inadequate dispensing fees.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Alcon’s global headquarters to move ahead of Novartis spinoff

BY Sandra Levy

Alcon, a global leader in eye care and a division of Novartis, on Tuesday announced plans to locate its future global headquarters in the Canton of Geneva, Switzerland, following completion of its proposed spinoff from Novartis. Alcon corporate and EMEA employees will begin moving to the new Geneva location in 2019.

Earlier this year, Novartis announced its intention to spinoff Alcon into a separately-traded standalone company.

Alcon’s new global headquarters in Geneva will be the primary location for Alcon’s senior corporate leadership and other corporate and commercial functions. It will be co-located with Alcon’s Europe, Middle East, and Africa (EMEA) regional office, which is already based in the city.

“We are delighted to announce Geneva as the location of Alcon’s new global headquarters following the proposed spinoff from Novartis,” Alcon’s chief executive officer, David Endicott said. “For more than 40 years, Alcon has had a significant presence in Switzerland, which is known for its progressive business climate and innovation-friendly policies. Being headquartered in Geneva will help further increase Alcon’s global scale and reach to better serve our customers.”

The new listed holding company for the Alcon group after the proposed spinoff will be incorporated in the Canton of Fribourg, where Alcon already has significant operations, which will complement other key sites in Rotkreuz and Schaffhausen.

Alcon could employ up to 700 in Switzerland post-spin-off. Alcon’s current global divisional headquarters in Fort Worth, Texas, will remain a major operational, commercial, and innovation hub for the proposed standalone company, according to the company.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?